Developer docs
API playgroundTry for free, no card

Search company profiles

Croen

Full company profile

uuid002yjxw

Namestring
Croen
Legal namestring
HLB bioCode Inc.
Websiteurl
croen.co.kr
Company typeenum
Public
Founded yearint
2009
Descriptiontext

Croen (operating as HLB bioCode Inc., 에이치엘비바이오코드) is a preclinical Contract Research Organization headquartered in Suwon, Gyeonggi-do, South Korea, founded in 2009. The company delivers GLP-certified preclinical testing services to pharmaceutical and biotechnology clients, spanning safety assessment in rodent and non-rodent species, toxicologic and clinical pathology, pharmacokinetic and toxicokinetic (PK/TK) bioanalytical evaluation, safety pharmacology, efficacy evaluation, and early-stage lead optimization screening. It also provides chemical substance registration evaluation under Korean regulatory frameworks (Chemical Substances Control Act and Chemical Registration and Evaluation Act, 화평법/화관법). Its technology platform is built on validated bioanalytical method development, formulation validation, and biological sample analysis with reliability assurance (신뢰성 보증) processes disclosed on the company's website.

The company generates revenue through project-based professional services contracts under a direct B2B sales-led motion, supported by dedicated business development personnel for non-clinical trial inquiries, GLP toxicology inquiries, and a structured online consultation system (trial consultation applications, visit consultation bookings, general inquiries). Customers are concentrated in two primary horizontal segments — pharmaceutical companies requiring GLP-certified safety and toxicology data for regulatory submissions, and biotechnology companies requiring preclinical efficacy and safety evaluation. Marketing is inquiry-based with no disclosed pricing; commercial engagement proceeds through direct email (bd@hlbbiocode.com) and phone, supplemented by an institutional website.

Croen holds publicly listed status on the Korean exchange, evidenced by regular shareholders' meetings (17th meeting notice issued March 10, 2026) and third-party stock issuance announcements (November 21, 2025). Active strategic MOUs include a genetic-disease drug development partnership with Medici Bio (March 2023), a strategic business cooperation with Nexcel (November 2022), and an academic knowledge-linkage with Seoul Hoseo Professional School's Companion Animal Science department (April 2021). Geographic footprint disclosed in source material is limited to South Korea (Gyeonggi Province), though the services support global pharmaceutical development programs.

Short descriptiontext

Croen (HLB bioCode Inc.) is a South Korean preclinical Contract Research Organization delivering GLP-certified safety assessment, toxicology, PK/TK bioanalysis, toxicologic pathology, efficacy evaluation, and chemical substance registration services to pharmaceutical and biotechnology clients.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersSeongnam, South Korea
HQ citystring
Seongnam
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical CRO services, GLP toxicology testing, pharmacokinetic analysis, safety pharmacology evaluation, drug development testing
Industry4 codes
PRIMARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAG
Medical Writing & Regulatory Submission Support CROs
NAICS code2 codes
  • Testing Laboratories and Services54138
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Testing Laboratories8734
Product category
Preclinical Contract Research Services (CRO)
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Preclinical CRO Services
TypeProfessional Services
Description

Contract research organization services providing GLP-certified preclinical testing including safety assessment, toxicology, PK/TK analysis, and efficacy evaluation for pharmaceutical and biotech clients. Revenue generated through project-based contracts for drug development studies.

hlbbiocode.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Croen (HLB bioCode) operates as a preclinical Contract Research Organization (CRO) providing GLP-certified drug development testing services. Its offerings cover safety assessment in rodent and non-rodent species, toxicologic and clinical pathology, PK/TK analysis and bioanalytical evaluation, safety pharmacology, efficacy evaluation, lead optimization screening, and chemical substance registration compliance under Korean chemical control laws. Services are delivered to pharmaceutical and biotechnology clients on a project-based contract basis.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Croen (HLB bioCode) operates as a preclinical Contract Research Organization (CRO) offering a unified platform of drug development services. The core offering is the Nonclinical CRO Business, supported by specialized testing modules including Safety Assessment (rodent/non-rodent), Toxicologic/Clinical Pathology, PK/TK Analysis and Pharmacokinetic & Analytical Evaluation Services, Safety Pharmacology Evaluation, Efficacy Evaluation, and Lead Optimization screening. Additional services include Chemical Substance Registration Evaluation for regulatory compliance. The company also provides GLP-certified testing and reliability assurance (신뢰성 보증) as part of its comprehensive service portfolio.

Product and service8 records
1Nonclinical CRO Business
CategoryPreclinical Contract Research Services (CRO)
Description

Contract research organization services providing comprehensive preclinical testing solutions for drug development, including safety assessment, toxicology, and pharmacokinetic evaluations. Targeted at pharmaceutical and biotechnology clients requiring regulatory-grade preclinical data for drug development and approval submissions.

2Pharmacokinetic & Analytical Evaluation
CategoryPreclinical testing services
Description

PK/TK analysis and bioanalytical services including analytical method development, feasibility testing, formulation validation (content, homogeneity, stability), concentration analysis, biological sample specificity and carry-over analysis, and pharmacokinetic/toxicokinetic parameter confirmation. For pharmaceutical and biotech R&D teams quantifying drug and metabolite concentrations.

3Safety Assessment (Rodents/Non-rodents)
CategoryPreclinical testing services
Description

Safety evaluation testing in rodent and non-rodent species for preclinical toxicity assessment of drug candidates. For pharmaceutical and biotech sponsors requiring GLP-compliant general toxicology studies.

4Toxicologic Pathology / Clinical Pathology
CategoryPreclinical testing services
Description

Pathology evaluation services combining toxicologic and clinical pathology expertise for preclinical safety assessment. Provides expert interpretation of histopathology, hematology, and clinical chemistry findings for drug development programs.

5Safety Pharmacology Evaluation
CategoryPreclinical testing services
Description

Safety pharmacology assessment services evaluating potential adverse effects of drug candidates on vital organ systems (cardiovascular, central nervous system, respiratory). For sponsors needing ICH S7-aligned safety pharmacology data packages.

6Efficacy Evaluation
CategoryPreclinical testing services
Description

Pharmacological efficacy assessment services to demonstrate therapeutic potential of drug candidates through in vivo/in vitro pharmacology studies. For pharmaceutical and biotech sponsors requiring proof-of-concept efficacy data.

7Lead Optimization (Early-Stage Drug Development Screening)
CategoryPreclinical testing services
Description

Early-stage drug development screening and lead optimization services to identify and refine promising drug candidates before formal preclinical toxicology studies. For pharmaceutical and biotech R&D teams advancing candidates from discovery toward development.

8Chemical Substance Registration Evaluation (Compliance with Chemical Substances Control Act / Chemical Registration and Evaluation Act)
CategoryRegulatory compliance services
Description

Regulatory compliance evaluation services for chemical substance registration under Korean chemical regulations (화평법/화관법). For chemical manufacturers and importers requiring regulatory dossiers for product placement in the Korean market.

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-03-17
Description

Croen signed MOU with Medici Bio for collaborative development of genetic disease drugs. This strategic partnership focuses on developing novel therapeutics for genetic diseases, combining Croen's preclinical expertise with Medici Bio's research capabilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-25
Description

Croen entered into strategic business cooperation MOU with Nexcel. This partnership aims to leverage combined capabilities for enhanced service offerings in the preclinical and pharmaceutical development space.

3Seoul Hoseo Professional School Department of Companion Animal Science (서울호서전문학교 반려동물학과)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-04-28
Description

Croen established knowledge linkage MOU with Seoul Hoseo Professional School's Companion Animal Science department. This collaboration supports academic-industry knowledge exchange in the veterinary and animal health sector.

hlbbiocode.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Asia-based CRO providing preclinical, bioanalytical, and drug discovery services. Direct competitor in preclinical safety and PK/TK work, especially for cross-border Korean biotech sponsors.

TypeBroad incumbent
Description

Asia-based global CRO/CDMO with extensive preclinical safety, bioanalytical, and PK services. A key regional competitor for Korean biotech preclinical work, with much larger capacity.

TypeBroad incumbent
Description

Mid-sized global CRO with preclinical and clinical operations. While more clinical-focused, it competes for Korean biotech sponsor preclinical planning and bundled program work.

TypeBroad incumbent
Description

Global testing services group with significant bioanalytical and pharmaceutical testing operations. Competes with Croen in bioanalytical method development and chemical registration testing services.

TypeDirect peer
Description

Asia-headquartered CRO offering bioanalytical, preclinical, and clinical services. Closely comparable in scale and service mix to Croen, particularly around bioanalytical/PK and safety assessment.

6PRC Eurofins (Eurofins Korea)
TypeRegional player
Description

Korean arm of Eurofins offering pharmaceutical and chemical testing services locally. Direct regional competitor for Croen's bioanalytical and chemical registration testing in the Korean market.

TypeBroad incumbent
Description

Global preclinical CRO offering safety assessment, toxicology, and research models services. Direct overlap with Croen's GLP toxicology and safety pharmacology offerings, but at vastly larger scale and geographic reach.

TypeBroad incumbent
Description

Full-service global CRO with significant preclinical and clinical capabilities. Competes with Croen for nonclinical safety and PK/TK studies from Korean biotech clients with global development programs.

TypeRegional player
Description

Major Korean testing and certification body with chemical and life sciences testing capacity. Overlaps with Croen's chemical substance registration testing work under Korean chemical regulations.

TypeDirect peer
Description

Korean preclinical CRO specializing in GLP toxicology and safety assessment — a direct domestic peer with overlapping service portfolio and similar regulatory positioning.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Croen

Preclinical Contract Research Services (CRO)croen.co.kr

Croen (HLB bioCode Inc.) is a South Korean preclinical Contract Research Organization delivering GLP-certified safety assessment, toxicology, PK/TK bioanalysis, toxicologic pathology, efficacy evaluation, and chemical substance registration services to pharmaceutical and biotechnology clients.

What Croen does

Croen (operating as HLB bioCode Inc., 에이치엘비바이오코드) is a preclinical Contract Research Organization headquartered in Suwon, Gyeonggi-do, South Korea, founded in 2009. The company delivers GLP-certified preclinical testing services to pharmaceutical and biotechnology clients, spanning safety assessment in rodent and non-rodent species, toxicologic and clinical pathology, pharmacokinetic and toxicokinetic (PK/TK) bioanalytical evaluation, safety pharmacology, efficacy evaluation, and early-stage lead optimization screening. It also provides chemical substance registration evaluation under Korean regulatory frameworks (Chemical Substances Control Act and Chemical Registration and Evaluation Act, 화평법/화관법). Its technology platform is built on validated bioanalytical method development, formulation validation, and biological sample analysis with reliability assurance (신뢰성 보증) processes disclosed on the company's website.

The company generates revenue through project-based professional services contracts under a direct B2B sales-led motion, supported by dedicated business development personnel for non-clinical trial inquiries, GLP toxicology inquiries, and a structured online consultation system (trial consultation applications, visit consultation bookings, general inquiries). Customers are concentrated in two primary horizontal segments — pharmaceutical companies requiring GLP-certified safety and toxicology data for regulatory submissions, and biotechnology companies requiring preclinical efficacy and safety evaluation. Marketing is inquiry-based with no disclosed pricing; commercial engagement proceeds through direct email (bd@hlbbiocode.com) and phone, supplemented by an institutional website.

Croen holds publicly listed status on the Korean exchange, evidenced by regular shareholders' meetings (17th meeting notice issued March 10, 2026) and third-party stock issuance announcements (November 21, 2025). Active strategic MOUs include a genetic-disease drug development partnership with Medici Bio (March 2023), a strategic business cooperation with Nexcel (November 2022), and an academic knowledge-linkage with Seoul Hoseo Professional School's Companion Animal Science department (April 2021). Geographic footprint disclosed in source material is limited to South Korea (Gyeonggi Province), though the services support global pharmaceutical development programs.

Croen firmographics

Firmographics
Name
Croen
Legal name
HLB bioCode Inc.
Website
https://croen.co.kr
Company type
Public
Founded year
2009
Operating status
Operating
Short description
Croen (HLB bioCode Inc.) is a South Korean preclinical Contract Research Organization delivering GLP-certified safety assessment, toxicology, PK/TK bioanalysis, toxicologic pathology, efficacy evaluation, and chemical substance registration services to pharmaceutical and biotechnology clients.
Ownership category
akta.pro rank

Croen industry classification

Industry
Product category
Preclinical Contract Research Services (CRO)
NAICS
Testing Laboratories and Services (54138), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAG
Medical Writing & Regulatory Submission Support CROs

Keywords

  • Preclinical CRO services
  • GLP toxicology testing
  • Pharmacokinetic analysis
  • Safety pharmacology evaluation
  • Drug development testing

Where Croen is headquartered

Location

Headquarters

HQ city
Seongnam
HQ country
South Korea
HQ region
Asia

Offices1 record

Markets served

Croen business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Preclinical CRO Services: Contract research organization services providing GLP-certified preclinical testing including safety assessment, toxicology, PK/TK analysis, and efficacy evaluation for pharmaceutical and biotech clients. Revenue generated through project-based contracts for drug development studies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Croen product offering

Product offering

Core offering

Croen (HLB bioCode) operates as a preclinical Contract Research Organization (CRO) providing GLP-certified drug development testing services. Its offerings cover safety assessment in rodent and non-rodent species, toxicologic and clinical pathology, PK/TK analysis and bioanalytical evaluation, safety pharmacology, efficacy evaluation, lead optimization screening, and chemical substance registration compliance under Korean chemical control laws. Services are delivered to pharmaceutical and biotechnology clients on a project-based contract basis.

Product overview

Croen (HLB bioCode) operates as a preclinical Contract Research Organization (CRO) offering a unified platform of drug development services. The core offering is the Nonclinical CRO Business, supported by specialized testing modules including Safety Assessment (rodent/non-rodent), Toxicologic/Clinical Pathology, PK/TK Analysis and Pharmacokinetic & Analytical Evaluation Services, Safety Pharmacology Evaluation, Efficacy Evaluation, and Lead Optimization screening. Additional services include Chemical Substance Registration Evaluation for regulatory compliance. The company also provides GLP-certified testing and reliability assurance (신뢰성 보증) as part of its comprehensive service portfolio.

Differentiator

Problem solved

Functional benefit

Products and services

  • Nonclinical CRO Business Contract research organization services providing comprehensive preclinical testing solutions for drug development, including safety assessment, toxicology, and pharmacokinetic evaluations. Targeted at pharmaceutical and biotechnology clients requiring regulatory-grade preclinical data for drug development and approval submissions.
  • Pharmacokinetic & Analytical Evaluation PK/TK analysis and bioanalytical services including analytical method development, feasibility testing, formulation validation (content, homogeneity, stability), concentration analysis, biological sample specificity and carry-over analysis, and pharmacokinetic/toxicokinetic parameter confirmation. For pharmaceutical and biotech R&D teams quantifying drug and metabolite concentrations.
  • Safety Assessment (Rodents/Non-rodents) Safety evaluation testing in rodent and non-rodent species for preclinical toxicity assessment of drug candidates. For pharmaceutical and biotech sponsors requiring GLP-compliant general toxicology studies.
  • Toxicologic Pathology / Clinical Pathology Pathology evaluation services combining toxicologic and clinical pathology expertise for preclinical safety assessment. Provides expert interpretation of histopathology, hematology, and clinical chemistry findings for drug development programs.
  • Safety Pharmacology Evaluation Safety pharmacology assessment services evaluating potential adverse effects of drug candidates on vital organ systems (cardiovascular, central nervous system, respiratory). For sponsors needing ICH S7-aligned safety pharmacology data packages.
  • Efficacy Evaluation Pharmacological efficacy assessment services to demonstrate therapeutic potential of drug candidates through in vivo/in vitro pharmacology studies. For pharmaceutical and biotech sponsors requiring proof-of-concept efficacy data.
  • Lead Optimization (Early-Stage Drug Development Screening) Early-stage drug development screening and lead optimization services to identify and refine promising drug candidates before formal preclinical toxicology studies. For pharmaceutical and biotech R&D teams advancing candidates from discovery toward development.
  • Chemical Substance Registration Evaluation (Compliance with Chemical Substances Control Act / Chemical Registration and Evaluation Act) Regulatory compliance evaluation services for chemical substance registration under Korean chemical regulations (화평법/화관법). For chemical manufacturers and importers requiring regulatory dossiers for product placement in the Korean market.

Companies that use Croen

Customer profile

Segments2 records

Ideal customer profiles3 records

Croen technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Croen partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Medici Bio (메디치바이오)coreStrategic or Co-development Partner · 17 March 2023Croen signed MOU with Medici Bio for collaborative development of genetic disease drugs. This strategic partnership focuses on developing novel therapeutics for genetic diseases, combining Croen's preclinical expertise with Medici Bio's research capabilities.
  • Nexcel (넥셀)coreStrategic or Co-development Partner · 25 November 2022Croen entered into strategic business cooperation MOU with Nexcel. This partnership aims to leverage combined capabilities for enhanced service offerings in the preclinical and pharmaceutical development space.
  • Seoul Hoseo Professional School Department of Companion Animal Science (서울호서전문학교 반려동물학과)minorStrategic or Co-development Partner · 28 April 2021Croen established knowledge linkage MOU with Seoul Hoseo Professional School's Companion Animal Science department. This collaboration supports academic-industry knowledge exchange in the veterinary and animal health sector.

Recent moves5 records

Expansion highlights4 records

Croen competitors and assessment

Company assessment

Direct peers

  • ChemPartner: Asia-based CRO providing preclinical, bioanalytical, and drug discovery services. Direct competitor in preclinical safety and PK/TK work, especially for cross-border Korean biotech sponsors.
  • Frontage Holdings: Asia-headquartered CRO offering bioanalytical, preclinical, and clinical services. Closely comparable in scale and service mix to Croen, particularly around bioanalytical/PK and safety assessment.
  • Biotoxtech: Korean preclinical CRO specializing in GLP toxicology and safety assessment — a direct domestic peer with overlapping service portfolio and similar regulatory positioning.

Broad incumbents

  • Wuxi AppTec: Asia-based global CRO/CDMO with extensive preclinical safety, bioanalytical, and PK services. A key regional competitor for Korean biotech preclinical work, with much larger capacity.
  • Medpace Holdings: Mid-sized global CRO with preclinical and clinical operations. While more clinical-focused, it competes for Korean biotech sponsor preclinical planning and bundled program work.
  • Eurofins Scientific: Global testing services group with significant bioanalytical and pharmaceutical testing operations. Competes with Croen in bioanalytical method development and chemical registration testing services.
  • Charles River Laboratories: Global preclinical CRO offering safety assessment, toxicology, and research models services. Direct overlap with Croen's GLP toxicology and safety pharmacology offerings, but at vastly larger scale and geographic reach.
  • Labcorp Drug Development (formerly Covance): Full-service global CRO with significant preclinical and clinical capabilities. Competes with Croen for nonclinical safety and PK/TK studies from Korean biotech clients with global development programs.

Regional players

  • PRC Eurofins (Eurofins Korea): Korean arm of Eurofins offering pharmaceutical and chemical testing services locally. Direct regional competitor for Croen's bioanalytical and chemical registration testing in the Korean market.
  • Korea Testing & Research Institute (KTR): Major Korean testing and certification body with chemical and life sciences testing capacity. Overlaps with Croen's chemical substance registration testing work under Korean chemical regulations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Croen compliance and trust

Trust signal

Compliance1 record

Croen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Croen leadership team

Management profile

Number of profiles

Croen funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Croen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Croen

What does Croen do?

Croen (HLB bioCode) operates as a preclinical Contract Research Organization (CRO) providing GLP-certified drug development testing services. Its offerings cover safety assessment in rodent and non-rodent species, toxicologic and clinical pathology, PK/TK analysis and bioanalytical evaluation, safety pharmacology, efficacy evaluation, lead optimization screening, and chemical substance registration compliance under Korean chemical control laws. Services are delivered to pharmaceutical and biotechnology clients on a project-based contract basis.

Is Croen a public or private company?

Croen is a public company. It is classified as public and is currently operating.

When was Croen founded?

Croen was founded in 2009.

Where is Croen based?

Croen is headquartered in Seongnam, South Korea, in the Asia region.

How does Croen make money?

One revenue line is on record: preclinical CRO Services.

Who are Croen's main competitors?

Direct peers on record are ChemPartner, Frontage Holdings and Biotoxtech. Broad incumbents are Wuxi AppTec, Medpace Holdings, Eurofins Scientific, Charles River Laboratories and Labcorp Drug Development (formerly Covance). Regional players are PRC Eurofins (Eurofins Korea) and Korea Testing & Research Institute (KTR).

Does Croen have an API?

No public API is recorded for Croen.

What industry is Croen in?

Croen's product category is Preclinical Contract Research Services (CRO). Its primary akta.pro industry code is HLAGAAAC, Toxicology & Safety Assessment CROs (GLP), with a secondary code of HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity). Its NAICS code is 54138 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales